Methylprednisolone and Mycophenolate mofetil ( DrugBank: Mycophenolate mofetil, Methylprednisolone, Mycophenolate )
2 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
93 | Primary biliary cholangitis | 1 |
95 | Autoimmune hepatitis | 1 |
93. Primary biliary cholangitis
Clinical trials : 298 / Drugs : 252 - (DrugBank : 59) / Drug target genes : 35 - Drug target pathways : 115
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04933292 (ClinicalTrials.gov) | June 16, 2021 | 1/5/2020 | A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome | A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome | Autoimmune Hepatitis;Primary Biliary Cirrhosis | Drug: Methylprednisolone and Mycophenolate mofetil;Drug: Methylprednisolone and azathioprine | Xiaoli Fan | NULL | Recruiting | 18 Years | 70 Years | All | 78 | Phase 4 | China |
95. Autoimmune hepatitis
Clinical trials : 52 / Drugs : 68 - (DrugBank : 27) / Drug target genes : 18 - Drug target pathways : 111
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04933292 (ClinicalTrials.gov) | June 16, 2021 | 1/5/2020 | A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome | A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome | Autoimmune Hepatitis;Primary Biliary Cirrhosis | Drug: Methylprednisolone and Mycophenolate mofetil;Drug: Methylprednisolone and azathioprine | Xiaoli Fan | NULL | Recruiting | 18 Years | 70 Years | All | 78 | Phase 4 | China |